Patents Examined by Zachary J Miknis
  • Patent number: 10316060
    Abstract: Nanostructures comprising ?-conjugated peptides for energy migration in aqueous environments are disclosed. Conductive material comprising these nanostructures, and supramolecular assemblies comprising covalently-bound electron donor-acceptor chromophores for photoinduced electron transfer also are disclosed.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: June 11, 2019
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: John D. Tovar, Howard E. Katz, Herdeline Ann M. Ardona, Allix Sanders, Kalpana Besar
  • Patent number: 10314911
    Abstract: The present system is directed in several embodiments to a method of administration of a therapeutic composition for protection of the brain of a subject at risk of injury leading to traumatic brain injury (TBI) and/or treatment of injury to the brain resulting from TBI. The method includes administering one or more therapeutic compositions comprising an effective amount of insulin directly to the subject patient's CNS, with no to minimal systemic exposure. Preferably, this method comprises administration of an effective amount of insulin to the upper third of a patient's nasal cavity, thereby bypassing the patient's blood-brain barrier and delivering the therapeutic composition directly to the patient's central nervous system.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: June 11, 2019
    Assignees: HealthPartners Research & Education, The Henry M. Jackson Foundation for Advancement of Military Medicine, Inc.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Kimberly Byrnes, Fiona Brabazon
  • Patent number: 10308926
    Abstract: Provided herein are polypeptides containing stabilized therapeutic peptides related to enhancer of zeste homolog 2 (EZH2), histone lysine N-methyltransferase. Also provided are compositions containing these polypeptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the polypeptides.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 4, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Loren D. Walensky, Gregory H. Bird, Woojin Kim, Stuart Orkin
  • Patent number: 10301629
    Abstract: Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS.
    Type: Grant
    Filed: June 11, 2014
    Date of Patent: May 28, 2019
    Assignee: PORTAGE PHARMACEUTICALS LTD.
    Inventors: Bruce H. Littman, John F. Thompson, Frank W. Marcoux
  • Patent number: 10294271
    Abstract: Molecular probe suitable for quantification of caspase activity in vivo using positron emission tomography (PET). Embodiments of the present invention can detect apoptosis in tumors and as a novel, potentially translatable biomarker for predicting response to personalized medicine.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: May 21, 2019
    Assignee: Vanderbilt University
    Inventors: H. Charles Manning, Matthew R. Hight
  • Patent number: 10293083
    Abstract: The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 21, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Wei Yang Seow
  • Patent number: 10294284
    Abstract: The present invention relates to a method for recombinant production of a C1q protein or a variant of the C1q protein, in which the protein is recovered from an in vitro culture of cells expressing a C1qA subunit or a variant of the C1qA subunit, a C1qB subunit or a variant of the C1qB subunit, and a C1qC subunit or a variant of the C1qC subunit, in which at least one of the subunits or subunit variants also has at the N-terminus or C-terminus a sequence of amino acids of at least six residues, at least 40% of which are glutamic acid and/or aspartic acid residues.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: May 21, 2019
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, INSTITUT NATIONAL DE LA SANTE DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Nicole Thielens, Isabelle Bally
  • Patent number: 10294268
    Abstract: The present invention relates to recombinant proteins/peptides from plant and animal materials, compositions comprising the proteins/peptides and methods for making them.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: May 21, 2019
    Assignee: PROTEINS EASY CORP.
    Inventors: Illimar Altosaar, Trevor Greenham
  • Patent number: 10294272
    Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: May 21, 2019
    Assignee: Pharis Biotec GmbH
    Inventors: Wolf-Georg Forssmann, Frank Kirchhoff, Jan Münch, Ludger Ständker
  • Patent number: 10294274
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are specific for the human and rat protease plasma kallikrein and are modified in one or two peptide loops to enhance potency and/or protease resistance.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: May 21, 2019
    Assignee: BicycleRD Limited
    Inventors: Daniel Teufel, Catherine Stace, Edward Walker
  • Patent number: 10294285
    Abstract: Novel compositions of recombinant human CC10 protein have been generated by chemically modifying the pure protein in vitro. Several new synthetic preparations containing isoforms of chemically modified rhCC10 have been generated by processes that utilize reactive oxygen species and reactive nitrogen species. These preparations contain novel isoforms of rhCC10 which have been characterized with enhanced or altered biological properties compared to the unmodified protein. Preparations containing novel isoforms may be used as standards to identify and characterize naturally occurring isoforms of native CC10 protein from blood or urine and ultimately to measure new CC10-based biomarkers to assess patient disease status. These preparations may also be used to treat respiratory, autoimmune, inflammatory, and other medical conditions that are not effectively treated with the unmodified protein.
    Type: Grant
    Filed: July 17, 2016
    Date of Patent: May 21, 2019
    Inventors: Aprile L. Pilon-Clayton, Humcha K. Hariprakasha, Richard S. Clayton, Melissa E. Winn
  • Patent number: 10294286
    Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: May 21, 2019
    Assignee: OMEROS CORPORATION
    Inventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
  • Patent number: 10286110
    Abstract: The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and/or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 14, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Wei Yang Seow
  • Patent number: 10287341
    Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: May 14, 2019
    Assignee: The University Court of the University of Aberdeen
    Inventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
  • Patent number: 10286032
    Abstract: Described have herein are peptide analogs of a prominin-1 peptide, DRVQRQTTTVVA (SEQ. ID. NO:1) which have enhanced regenerative and/or angiogenesis activity, increase VEGF binding to endothelial cells, and/or increase wound healing activity relative to the peptide of SEQ ID NO: 1. Provided herein are fusion proteins and compositions comprising these peptide analogs and uses thereof.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: May 14, 2019
    Assignee: Children's Medical Center Corporation
    Inventors: Avner Adini, Robert D'Amato
  • Patent number: 10286111
    Abstract: The present invention relates to hydrogels comprising a plurality of amphiphilic peptides and/or peptoids capable of self-assembling into three-dimensional macromolecular nanofibrous networks, which entrap water and form said hydrogels, wherein at least a portion of said plurality of amphiphilic peptides and/or peptoids is chemically cross-linked. The present invention further relates to methods for preparing such hydrogels and to various uses of such hydrogels, e.g. as cell culture substrates, for drug and gene delivery, as wound dressing, as an implant, as an injectable agent that gels in situ, in pharmaceutical or cosmetic compositions, in regenerative medicine, in tissue engineering and tissue regeneration, or in electronic devices. It also relates to a method of tissue regeneration or tissue replacement using a hydrogel in accordance with the present invention.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: May 14, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Wei Yang Seow
  • Patent number: 10201595
    Abstract: Compositions and methods for the treatment and/or prevention of disorders associated with C1 esterase inhibitor deficiency are disclosed.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 12, 2019
    Assignee: Shire ViroPharma Incorporated
    Inventors: Stephen Ruddy, Mark Cornell Manning, Ryan Erik Holcomb
  • Patent number: 10179194
    Abstract: The present invention relates to the use of peptides, peptoids and/or peptidomimetics capable of self-assembling and forming a (nanofibrous) hydrogel in biofabrication. The present invention further relates to methods for preparing hydrogels and to methods for preparing continuous fibres and to methods for obtaining multi-cellular constructs with defined, precise geometrics. The present invention further relates to various uses of such hydrogels for obtaining mini-hydrogel arrays and 3D organoid structures or 3D macromolecular biological constructs.
    Type: Grant
    Filed: December 1, 2014
    Date of Patent: January 15, 2019
    Assignee: Agency for Science, Technology and Research
    Inventors: Charlotte Hauser, Yihua Loo
  • Patent number: 10172923
    Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: January 8, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
  • Patent number: 10159716
    Abstract: Surfactant protein D (SP-D) is a member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD).
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 25, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Jeffrey A. Whitsett, Machiko Ikegami